SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bockmann B, Grill HJ, Giesing M. Molecular characterization of minimal residual cancer cells in patients with solid tumors. Biomol Eng. 2001; 17: 95111.
  • 2
    Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res. 1999; 5: 19501960.
  • 3
    Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br J Dermatol. 1999; 141: 3036.
  • 4
    Palmieri G, Strazzullo M, Ascierto PA, Satriano SM, Daponte A, Castello G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol. 1999; 17: 304311.
  • 5
    Peck K, Sher YP, Shih JY, Roffler SR, Wu CW, Yang PC. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res. 1998; 58: 27612765.
  • 6
    Krismann M, Todt B, Schroder J, et al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol. 1995; 13: 27692775.
  • 7
    Henke W, Jung M, Jung K, et al. Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int J Cancer. 1997; 70: 5256.
  • 8
    Thiounn N, Saporta F, Flam TA, et al. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology. 1997; 50: 245250.
  • 9
    Gala JL, Heusterspreute M, Loric S, et al. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. Clin Chem. 1998; 44: 472481.
  • 10
    Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999; 340: 265271.
  • 11
    Wang D, Yeger H, Cutz E. Expression of gastrin-releasing peptide receptor gene in developing lung. Am J Respir Cell Mol Biol. 1996; 14: 409416.
  • 12
    Spurzem JR, Rennard SI, Romberger DJ. Bombesin-like peptides and airway repair: a recapitulation of lung development? Am J Respir Cell Mol Biol. 1997; 16: 209211.
  • 13
    Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985; 316: 823826.
  • 14
    Miyake Y, Kodama T, Yamaguchi K. Pro-gastrin-releasing peptide(31–98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res. 1994; 54: 21362140.
  • 15
    Aoyagi K, Miyake Y, Urakami K, et al. Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31–98) as tumor marker for small-cell lung carcinoma: development and evaluation. Clin Chem. 1995; 41: 537543.
  • 16
    Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3. 1973; 4: 3142.
  • 17
    Corjay MH, Dobrzanski DJ, Way JM, et al. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem. 1991; 266: 1877118779.
  • 18
    DeMichele MA, Davis AL, Hunt JD, Landreneau RJ, Siegfried JM. Expression of mRNA for three bombesin receptor subtypes in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 1994; 11: 6674.
  • 19
    Spindel ER, Chin WW, Price J, Rees LH, Besser GM, Habener JF. Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. Proc Natl Acad Sci U S A. 1984; 81: 56995703.
  • 20
    Bessho A, Tabata M, Kiura K, et al. Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by reverse transcriptase-polymerase chain reaction. Anticancer Res. 2000; 20: 11491154.
  • 21
    Lacroix J, Becker HD, Woerner SM, Rittgen W, Drings P, von Knebel Doeberitz M. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR. Int J Cancer. 2001; 92: 18.
  • 22
    Zippelius A, Pantel K. RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. Ann N Y Acad Sci. 2000; 906: 110123.
  • 23
    Tora M, Barbera VM, Real FX. Detection of HuD transcripts by means of reverse transcriptase and polymerase chain reaction: implications for the detection of minimal residual disease in patients with small cell lung cancer. Cancer Lett. 2000; 161: 157164.
  • 24
    Toi-Scott M, Jones CL, Kane MA. Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. Lung Cancer. 1996; 15: 341354.